| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 14.1 | 14.3 |
| Net income | -4.7 | -3.7 |
| EPS (diluted, $ a share) | $-0.38 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -1.3% |
|---|---|
| Operating margin | -10.1% |
10-Q filed with the SEC, NASDAQ: LNSR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
LENSAR, Inc.: key numbers
- Share price
- $5.29Close, Nov 16
- Market cap
- $65M
- Shares outstanding
- 12.29MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from LENSAR, Inc.
All →LENSAR Financial Results
LENSAR reported third quarter 2026 financial results, highlighted by a 17% year-over-year increase in recurring revenue to $12.6 million despite a slight 1% decline in total revenue due to seasonal factors. The company expanded its ALLY System installed base to 225 units and reported a total laser installed base of 450 systems. While the company saw a net loss of $4.7 million, Adjusted EBITDA improved to $1.7 million compared to a loss in the prior year period.
- Term
- Q3 2026
“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter.”
Nick Curtis, President and CEO of LENSAR
“Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue.”
Nick Curtis, President and CEO of LENSAR